

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/10893 A2

- (51) International Patent Classification⁷: C07K 4/00 (US). KORNFELD, Hardy; 5 Garrison Road, Wellesley Hills, MA 02481 (US).
- (21) International Application Number: PCT/US00/21317
- (22) International Filing Date: 4 August 2000 (04.08.2000) (74) Agents: GROLZ, Edward, W. et al.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Garden City, NY 11530 (US).
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/368,630 5 August 1999 (05.08.1999) US (81) Designated States (*national*): CA, JP, MX.
- (71) Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. [US/US]; 101 North Wilmot Road, Suite 600, Tucson, AZ 85711-3335 (US). Published: — Without international search report and to be republished upon receipt of that report.
- (72) Inventors: CENTER, David, M.; Three Caroline Street, Wellesley Hills, MA 02181 (US). CRUIKSHANK, William, W.; 13 Butternut Road, Westford, MA 01886 For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/10893 A2

(54) Title: IL-16 ANTAGONISTS

(57) Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

IL-16 ANTAGONISTS

5 The present invention relates to IL-16
antagonists and the use thereof for the treatment of
IL-16 mediated disorders such as certain inflammatory
diseases. In particular, the present invention relates
to the discovery of IL-16 antagonist peptides whose
10 sequences coincide with the C-terminal region of IL-16.

Interleukin-16 (IL-16), previously named
lymphocyte chemoattractant factor (or LCF), is a pro-
inflammatory lymphokine with chemoattractant activity
15 for resting CD4⁺ T lymphocytes. Subsequent studies
indicate that IL-16 activates signal transduction in
CD4⁺ target cells including monocytes, eosinophils and
pro-B cells, and stimulates a variety of biological
activities in addition to chemotaxis. Among these
20 activities are inhibition of retroviral replication
(Maciaszek, et al., *J. Immunol.* 158:5, 1997; Zhou, et
al., *Nature Medicine* 3:659, 1997 and Baier, et al.,
Nature 378:563, 1995), upregulation of IL-2R and
synergy with IL-2 for CD4⁺ T cell proliferation
25 (Parada, et al., *J. Immunol.* 160:2115, 1998), induction
of RAG-1 and RAG-2 expression in CD4⁺ pro-B cells
(Szabo, et al., *J. Immunol.*, 161:2248, 1998), and
transient inhibition of Mixed Lymphocyte Reaction
(MLR) (Theodore, et al., *J. Immunol.* 157:1958, 1996).
30 Investigation of certain human diseases and
experimental murine models indicates that IL-16
participates in inflammatory conditions characterized

by tissue recruitment of CD4⁺ T lymphocytes and other CD4⁺ cell types. Conditions where IL-16 has been identified by ELISA and/or bioassay of body fluids, or by immunohistochemical and in situ hybridization techniques, include bronchial asthma (Laherge et al., *Am. J. Respir. Cell. Mol. Biol.* 17: 193, 1997), inflammatory bowel disease (Keates et al., *Gastroenterology* 112, A110, 1997), Graves' disease (Cruikshank et al., *J. Allergy Clin. Immunol.* 99: 554, 1997), multiple sclerosis (Biddison et al., *J. Immunol.* 158: 3046, 1997) and bullous pemphigoid (Center et al., *J. Invest. Dermatol.* 81: 204, 1983). IL-16 is also implicated in the pathogenesis of rheumatoid arthritis (Klimiuk et al., *J. Immunol.* 162: 4293-4299, 1999) and lupus (Lee et al., *British J. Rheumatology* 37: 1334-1337, 1998). Thus, it would be desirable to identify and/or generate reagents capable of interfering with the IL-16 activity for the purpose of treating inflammatory diseases.

The predicted amino acid sequence of IL-16 contains a central PDZ module, and structural studies confirm that IL-16 assumes a core PDZ-like conformation with flexible N-terminal and C-terminal tails of 17 and 14 residues, respectively (Muhlhahn et al., *Nature Structural Biology* 5:682, 1998)). A synthetic oligopeptide corresponding to the 16 C-terminal amino acids of human IL-16 (Arg106 to Ser121) has been reported to inhibit the chemoattractant activity of natural and recombinant human or murine IL-16 (Keane et al., *J. Immunol.* 160:5945, 1998).

The present invention demonstrates that a series of peptides corresponding to native or

substituted sequences of the C-terminus of IL-16 can inhibit IL-16 activity. Compositions and methods useful for treating IL-16 mediated disorders are exploited using these peptides.

5

One embodiment of the present invention is directed to IL-16 antagonists.

Another embodiment of the present invention is directed to IL-16 antagonist peptides.

10

The IL-16 antagonist peptides of the present invention are at least 4 amino acids in length and substantially correspond to the C-terminal sequence of human or murine IL-16 surrounding the Arg/Lys-Arg motif, i.e., R¹⁰⁶-R¹⁰⁷ of human IL-16, R¹⁰³-R¹⁰⁴ of murine IL-16 or K¹⁰⁶-R¹⁰⁷ of IL-16 from squirrel monkey, for example.

15

A preferred IL-16 antagonist peptide of the present invention is the tetrameric peptide X_{aa0}RX_{aa1}X_{aa2} (SEQ ID NO:1), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can be any amino acid. Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16, such as Lys or Thr for X_{aa1}, and Ser for X_{aa2}.

20

More preferably, X_{aa0}RX_{aa1}X_{aa2} is a tetramer having a sequence which coincides with the native sequence of a mammalian IL-16, e.g., RRKS (SEQ ID NO:2), RRTS (SEQ ID NO:3), or KRKS (SEQ ID NO:4). Even more preferably, such tetramer has Arg as the first amino acid. Homologs and analogs of the tetramers of SEQ ID NO:2-4 are also contemplated by the present invention. For example, analogs of RRKS (SEQ ID NO:2) include RRAS (SEQ ID NO:5) and RRKA (SEQ ID NO:6).

25

30

Another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:8), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can be any amino acid.

5 Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16, e.g., Val for X_{aa1} , and Ile or Leu for X_{aa2} .

10 More preferably, $X_{aa1}X_{aa2}X_{aa0}R$ is a tetramer having a sequence which coincides with the native sequence of a mammalian IL-16, such as VIRR (SEQ ID NO:9), VLRR (SEQ ID NO:10) and VIKR (SEQ ID NO:11). Even more preferably, such tetramer has Arg as the first amino acid. Homologs and analogs of these tetramers (SEQ ID NOS:9-11) are also contemplated by
15 the present invention.

Still another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:12), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can
20 be any one amino acid.

Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16. For example, X_{aa1} can be Ile or Leu, and X_{aa2} can be Lys or Thr.

25 More preferably, $X_{aa1}X_{aa2}X_{aa0}R$ is a tetramer having a sequence which coincides with the native sequence of an IL-16, such as IRRK (SEQ ID NO:13), IRRT (SEQ ID NO:14), LRRK (SEQ ID NO:15), and IKRK (SEQ ID NO:16). Even more preferably, such tetramer has Arg as
30 the first amino acid. Homologs and analogs of such tetramers are also contemplated by the present invention.

Further according to the present invention, an IL-16 antagonist peptide can be longer than a tetramer, as long as the such antagonist peptide contains one of the tetrameric sequences described hereinabove, i.e., $X_{aa0}RX_{aa1}X_{aa2}$ (SEQ ID NO:1), $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:8) or $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:12), and as long as such peptide antagonizes at least one IL-16 biological activity.

Nucleic acid molecules coding for any of the above IL-16 antagonist peptide of the present invention, expression vectors which include any of such nucleic acid molecules, as well as related host cells containing such nucleotide sequences or vectors, are also contemplated by the present invention.

In a further aspect, the present invention provides antibodies directed against the IL-16 antagonist peptides of the present invention.

Preferably, the antibodies of the present invention are raised against those IL-16 antagonist peptides whose sequences coincide with the corresponding sequences of a mammalian IL-16 protein, which antibodies can antagonize or neutralize the activity of IL-16. Both polyclonal antibodies and monoclonal antibodies are contemplated by the present invention.

Functional derivatives of the monoclonal antibodies of the present invention are also contemplated, including Fab, Fab', $F(ab')_2$, of the present mAbs, single chain antibodies, humanized antibodies and the like.

A related aspect of the present invention is directed to methods of raising antibodies specific for

the IL-16 antagonist peptides of the present invention by using such peptides as immunogens.

In another embodiment, the present invention provides pharmaceutical compositions which include one or more of the IL-16 antagonist peptides or antibodies, and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention can also include other appropriate active ingredients, such as known anti-inflammatory agents, e.g., anti-CD4 antibodies, anti-TNF α antibodies, NSAIDS, steroids, cyclosporin-A, or cytotoxic drugs.

Another aspect of the present invention provides methods of interfering with, blocking or otherwise preventing the interaction or binding of IL-16 with an IL-16 receptor by employing the IL-16 antagonists contemplated by the present invention.

In a further aspect, the present invention provides methods of treating an IL-16-mediated disorder in a subject by administering a therapeutically effective amount of a pharmaceutical composition of the present invention. In particular, IL-16-mediated disorders which can be treated by employing the methods of the present invention include asthma, rheumatoid arthritis, inflammatory bowel disease, Graves' disease, multiple sclerosis, lupus and bullous pemphigoid.

Figure 1 graphically depicts the structure of IL-16 and peptides used for inhibition studies. Mature IL-16 (released from pro-IL-16 by caspase-3 cleavage) is a 121 amino acid polypeptide consisting of a central PDZ-like domain flanked by N-terminal and C-terminal tails (*crosshatched*) of 17 and 14 residues,

respectively. The arginine residues at position 106 and 107 are within the boundary of the PDZ domain. The native terminal sequences are indicated below the cartoon. Oligopeptides corresponding to indicated C-terminal sequences from Arg¹⁰⁶ to Ser¹²¹ were prepared. Peptides made with alanine substitutions of the native sequence are indicated in boldface.

Figure 2 depicts the inhibition of IL-16-stimulated T cell motility by C-terminal peptides in chemotaxis assays using human T lymphocytes in the presence or absence of C-terminal peptides. **A**, IL-16 inhibition by oligopeptides corresponding to native IL-16 sequences. Cell migration in response to rIL-16 at concentrations of 10^{-9} M (*solid bar*), 10^{-10} M (*empty bar*) and 10^{-11} M (*crosshatched bar*) with or without peptides was compared to cell migration in response to control buffer (considered as 100%). Each of the indicated peptides was added at 10 μ g/ml. Ten high-power fields were counted and the mean obtained for each condition. Results are expressed as the mean % control migration $\pm$ SEM for three experiments. Comparisons between control and experimental conditions were analyzed by Student's *t* test; the asterisk indicates statistical significance ($P < 0.05$) for a difference in T cell migration at the indicated IL-16 concentration in the presence or absence of peptide. **B**, IL-16 inhibition by oligopeptides with alanine substitutions. Results are expressed as the mean % control migration $\pm$ SEM for four experiments.

Figure 3 depicts specific inhibition of IL-16 by peptides. T cells were stimulated with gp120 or Leu 3a at 0.5 μ g/ml (*solid bars*), 1.0 μ g/ml (*empty bars*)

and 5.0 µg/ml (*crosshatched bars*) in the presence or absence of peptide RRKS (10 µg/ml) as indicated. Results are expressed as the mean % control migration ± SEM for three experiments.

Figure 4 graphically depicts composition of recombinant IL-16 mutants generated by PCR mutagenesis and produced in *E. coli*. The native N-terminal and C-terminal sequences are represented as crosshatched bars flanking the central PDZ-like core. Deletions of 12 or 16 C-terminal residues and 12 or 22 N-terminal residues are shown in the figure. Mutants with single Alanine substitutions are also indicated.

Figure 5 depicts chemoattractant activity of mutated rIL-16. **A**, C-terminal and N-terminal deletion mutations. Concentrations of rIL-16 tested included 10^{-8} M (*solid bar*), 10^{-9} M (*empty bar*), 10^{-10} M (*crosshatched bar*) and 10^{-11} M (*stippled bar*). **B**, Chemoattractant activity of IL-16 constructs with C-terminal point mutations. The IL-16 point mutations included Arg¹⁰⁶ plus Arg¹⁰⁷ to alanine (*IAAK*), Arg¹⁰⁷ to alanine (*IRAK*), or Arg¹⁰⁶ to alanine (*IARK*).

Figure 6 depicts Western blot analysis of native and mutated rIL-16. Native rIL-16 and C-terminal IL-16 deletion mutant proteins were resolved by SDS/PAGE and transferred to nitrocellulose by electroblotting. Duplicate blots were probed with polyclonal rabbit anti-IL-16 (*upper panel*), or monoclonal anti-IL-16 (mAb 17.1; *lower panel*), detected with HRP-conjugated secondary Ab, and visualized by chemiluminescence. C-4 deletion (*lane 1*), C-8 (*lane*

2), C-12 (lane 3), C-16 (lane 4), native rIL-16 (lane 5).

Figure 7 depicts inhibition of the MLR by native rIL-16 or rIL-16 with C-terminal point mutations. Stimulator cells consisted of PBMC pre-treated with mitomycin C. Responder cells were T lymphocytes isolated from a different donor and incubated in control buffer (*No IL-16*), or pre-treated with native or mutated rIL-16 at 10^{-8} M (*black bars*), 10^{-9} M (*empty bars*), 10^{-10} M (*crosshatched bars*), or 10^{-11} M (*stippled bars*). The IL-16 point mutations included Arg¹⁰⁶ plus Arg¹⁰⁷ to alanine (*IAAK*), Arg¹⁰⁷ to alanine (*IRAK*), or Arg¹⁰⁶ to alanine (*IARK*). Cultures were pulsed with [³H]thymidine on day 5 and harvested on day 6 for scintigraphy. Results are expressed as mean cpm (with background subtracted) $\pm$ SD for three experiments.

Figure 8 depicts inhibition of MLR by IL-16 deletion mutants. Responder cells were pre-incubated in control buffer (*No IL-16*) or pre-treated with (10^{-8} M to 10^{-11} M) native rIL-16 or with the rIL-16 deletion constructs C-12, C-16, N-12, N-22, C-16 plus N-12, or C-16 plus N-22. Asterisks indicate a significant difference ($P < 0.05$) in mean cpm comparing cells pre-treated with native rIL-16 or mutated rIL-16 at the identical concentration.

Figure 9 depicts the IL-16 sequences from various species. The IL-16 sequences from African green monkey, rhesus monkey and mangleby are identical. The Arg/Lys-Arg motif is underlined.

In accordance with the present invention, it has been found that a series of peptides having

sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. Surprisingly, the present inventors have found that such IL-16-inhibiting peptides can be as short as 4 amino acids in length.

Accordingly, the present invention is directed to IL-16 antagonists. By "IL-16 antagonist" is meant any molecule that inhibits, suppresses or causes the cessation of at least one IL-16-mediated biological activity by, e.g., interfering with, blocking or otherwise preventing the interaction or binding of IL-16 to an IL-16 receptor, e.g., the CD4 receptor.

"An IL-16-mediated biological activity" as used herein includes chemotaxis of CD4⁺ cells such as CD4⁺ T cells, inhibition of retroviral replication (such as inhibition of HIV and SIV in infected PBMCs), upregulation of IL-2R on CD4⁺ T cells, synergy with IL-2 for CD4⁺ T cell proliferation, induction of RAG-1 and RAG-2 expression in CD4⁺ pro-B cells, and inhibition of Mixed Lymphocyte Reaction (MLR). These IL-16 mediated biological activities can be determined using the assays described by Cruikshank et al. (*Proc. Natl. Acad. Sci. USA* 91: 5109-5113, 1994); Maciaszek et al. (*J. Immunol.* 158:5, 1997), Zhou, et al. (*Nature Medicine* 3:659, 1997) and Baier et al. (*Nature* 378:563, 1995); Parada et al. (*J. Immunol.* 160:2115, 1998); Szabo et al. (*J. Immunol.*, 161:2248, 1998); and Theodore et al. (*J. Immunol.* 157:1958, 1996), respectively.

An IL-16 antagonist functions in two ways. The antagonist can compete with IL-16 for the cell surface receptor thereby interfering with, blocking or

otherwise preventing the binding of IL-16 to an IL-16 receptor. This type of antagonist, i.e., which binds the receptor but does not trigger signal transduction, is also referred to herein as a "competitive antagonist" and is a feature of the present invention. Alternatively, an IL-16 antagonist can bind to or sequester IL-16 with sufficient affinity and specificity to substantially interfere with, block or otherwise prevent binding of IL-16 to an IL-16 receptor, thereby inhibiting, suppressing or causing the cessation of at least one IL-16-mediated biological activity, such as T-cell chemotaxis, for example. This type of IL-16 antagonist is also termed a "sequestering antagonist".

According to the present invention, preferred IL-16 antagonists include peptides (referred to herein as "IL-16 antagonist peptides") and antibodies.

According to the present invention, an IL-16 antagonist peptide is at least 4 amino acids in length and substantially corresponds to the C-terminal sequence of human or murine IL-16 surrounding the Arg/Lys-Arg motif, i.e., R¹⁰⁶-R¹⁰⁷ of human IL-16, R¹⁰³-R¹⁰⁴ of murine IL-16 or K¹⁰⁶-R¹⁰⁷ of IL-16 from squirrel monkey and Aotus trivirgatus. The numbering of the amino acids are defined in accordance with the sequences of the mature, secreted form of IL-16. The sequences of the mature IL-16 from human and mouse have been described by Keane et al. (*J. Immunol* 160: 5945-5954, 1998). See also **Figure 9**. The sequences of the full-length pro-IL-16 from African green monkey, rhesus monkey, mangleby, zebu, macaque, squirrel monkey and Aotus trivirgatus have been published by the Genbank

database at the web site
<http://www.ncbi.nlm.nih.gov/Entrez/protein.html>. The
predicted sequences of the mature IL-16 from these
species are also included in **Figure 9**.

5 By "substantially corresponds to" is meant
peptides having sequences that are identical to the
native sequences of the C-terminal region of human or
murine IL-16 surrounding the Arg/Lys-Arg motif, as
well as homologs and analogs of such peptides.

10 By "homologs" is meant the corresponding
peptides from IL-16 proteins of other mammalian species
substantially homologous at the overall protein (i.e.,
mature protein) level to human or murine IL-16, so long
as such homolog peptides retain the IL-16 antagonist
15 property. The mammalian species can include African
green monkey, rhesus monkey, mangleby, zebu, macaque,
squirrel monkey and Aotus trivirgatus. According to
the present invention, the IL-16 sequences from
African green monkey, rhesus monkey and mangleby are
20 identical and share about 95% homology with human IL-
16, and about 82.1% homology with murine IL-16,
respectively.

By "substantial homologous" is meant the
degree of amino acid homology of at least about 65%,
25 preferably at least about 70%, and more preferably at
least about 75%, which degree is the similarity index
calculated using the Lipman-Pearson Protein Alignment
program with the following choice of parameters: Ktuple
= 2, Gap Penalty = 4, and Gap Length Penalty = 12.

30 According to the present invention, the IL-16
antagonist peptides of the present invention antagonize
human and murine IL-16 as well as IL-16 molecules of

other mammalian species that are substantially homologous to human or murine IL-16 proteins.

By "analogs" is meant peptides which differ by one or more amino acid alterations, which
5 alterations, e.g., substitutions, additions or deletions of amino acid residues, do not abolish the IL-16 antagonist properties of the relevant peptides.

Thus, an analog of a peptide can have one or more amino acid residues of the peptide substituted,
10 conservatively or non-conservatively. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as I, V, L or M for another; the substitution of one polar (hydrophilic) residue for another polar residue, such
15 as R for K, Q for N, G for S, or vice versa; and the substitution of a basic residue such as K, R or H for another or the substitution of one acidic residue such as D or E for another. Examples of non-conservative substitutions include the substitution of a non-polar
20 (hydrophobic) residue such as I, V, L, A, M for a polar (hydrophilic) residue such as C, Q, D, K and/or vice versa.

The phrase "analog" also includes the use of chemically derivatized residues in place of a non-
25 derivatized residue as long as the peptide retains the requisite IL-16 antagonist properties.

Analogs also include addition of amino acids to the N-terminus or C-terminus of a relevant peptide. For example, the addition of cysteine to the N- or C-
30 terminus of a peptide, by which, if desired, the peptide can be covalently attached to a carrier protein, e.g., albumin. Such attachment, it is

believed, can minimize clearing of the peptide from the blood and also prevent proteolysis of the peptides.

In addition, for purposes of the present invention, peptides containing D-amino acids in place
5 of L-amino acids are also included in the term "analogs". The presence of such D-isomers may help minimize proteolytic activity and clearing of the peptide.

A preferred IL-16 antagonist peptide of the
10 present invention is a tetrameric peptide having the sequence of $X_{aa0}RX_{aa1}X_{aa2}$ (SEQ ID NO:1), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can be any amino acid, which includes A = Ala = Alanine,

R = Arg = Arginine,

15 N = Asn = Asparagine,

D = Asp = Aspartic acid,

C = Cys = Cysteine,

Q = Gln = Glutamine,

E = Glu = Glutamic acid,

20 G = Gly = Glycine,

H = His = Histidine,

I = Ile = Isoleucine,

L = Leu = Leucine,

K = Lys = Lysine,

25 M = Met = Methionine,

F = Phe = Phenylalanine,

P = Pro = Proline,

S = Ser = Serine,

T = Thr = Threonine,

30 W = Trp = Tryptophan,

Y = Tyr = Tyrosine and

V = Val = Valine.

Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16. For example, X_{aa1} can be Lys (human, African green monkey, rhesus monkey, mangeby, zebu, macaque, squirrel monkey and Aotus trivirgatus) or Thr (murine), and X_{aa2} can be Ser (human, African green monkey, rhesus monkey, mangeby, zebu, macaque, squirrel monkey, Aotus trivirgatus and murine).

More preferably, $X_{aa0}RX_{aa1}X_{aa2}$ is a tetramer having a sequence which coincides with the native sequence of a mammalian IL-16. Examples of such tetrameric sequences include RRKS (SEQ ID NO:2) (human, African green monkey, rhesus monkey, mangeby, zebu and macaque), RRTS (SEQ ID NO:3) (murine), and KRKS (SEQ ID NO:4) (squirrel monkey and Aotus trivirgatus).

Even more preferably, $X_{aa0}RX_{aa1}X_{aa2}$ coincides with the native sequence of a mammalian IL-16 and X_{aa0} is Arg, for example, RRKS (SEQ ID NO:2) and RRTS (SEQ ID NO:3).

Homologs and analogs of any of these tetramers SEQ ID NOS:2-4 are also contemplated by the present invention. For example, analogs of tetramer RRKS (SEQ ID NO:2) of the present invention include RRAS (SEQ ID NO:5) and RRKA (SEQ ID NO:6), and an analog of RRTS (SEQ ID NO:3) is RRAS (SEQ ID NO:5) and RRTA (SEQ ID NO:7).

Another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:12), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can be any amino acid.

Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16. For

example, X_{aa1} can be Val (human, African green monkey, rhesus monkey, mangeby, zebu, macaque, squirrel monkey, Aotus trivirgatus and murine), and X_{aa2} can be Ile (human, African green monkey, rhesus monkey, mangeby, macaque, squirrel monkey, Aotus trivirgatus and murine), or Leu (zebu).

More preferably, $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:8) coincides with the native sequence of a mammalian IL-16. Examples of such tetrameric sequences include VIRR (SEQ ID NO:9) (human, African green monkey, rhesus monkey, mangeby, macaque and murine), VLRR (SEQ ID NO:10) (Zebu), and VIKR (SEQ ID NO:11) (squirrel monkey and Aotus trivirgatus).

Even more preferably, $X_{aa1}X_{aa2}X_{aa0}R$ coincides with the native sequence of a mammalian IL-16 and X_{aa0} is Arg, for example, VIRR (SEQ ID NO:9) and VLRR (SEQ ID NO:10).

Homologs and analogs of these tetramers (SEQ ID NOS: 9-11) are also contemplated by the present invention.

Still another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:12), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} can be any amino acid.

Preferably, X_{aa1} and X_{aa2} are those amino acids found in the native sequence of a mammalian IL-16. For example, X_{aa1} can be Ile (human, African green monkey, rhesus monkey, mangeby, macaque, squirrel monkey, Aotus trivirgatus and murine) or Leu (zebu), and X_{aa2} can be Lys (human, African green monkey, rhesus monkey,

mangeby, macaque, zebu, squirrel monkey and Aotus trivirgatus) or Thr (murine).

More preferably, $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:12) coincides with the native sequence of an IL-16.

5 Examples of such tetrameric sequences include IRRK (SEQ ID NO:13) (human, African green monkey, rhesus monkey, mangeby and macaque), LRRK (SEQ ID NO:15) (zebu), IKRK (SEQ ID NO:16) (squirrel monkey and Aotus trivirgatus), and IRRT (SEQ ID NO:14) (murine).

10 Even more preferably, $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:12) coincides with the native sequence of a mammalian IL-16 and X_{aa0} is Arg, for example, IRRK (SEQ ID NO:13), LRRK (SEQ ID NO:15) and IRRT (SEQ ID NO:14).

15 Homologs and analogs of such tetramers (SEQ ID NOS:13-16) are also contemplated by the present invention.

Further according to the present invention, an IL-16 antagonist peptide can be longer than a tetramer, as long as such antagonist peptide contains
20 one of the tetrameric sequences described hereinabove, i.e., $X_{aa0}RX_{aa1}X_{aa2}$ (SEQ ID NO:1), $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:12) or $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:8), and as long as such peptide antagonizes at least one IL-16 biological activity. Preferably, the peptides contain $X_{aa0}RX_{aa1}X_{aa2}$
25 (SEQ ID NO:1), more preferably, X_{aa0} is Arg in SEQ ID NO:1. Generally speaking, the peptide has less than 35 amino acids, preferably less than 25 amino acids, more preferably less than 16 amino acids. The peptides of the present invention does not include RRKSLQSKETTAAGDS
30 (SEQ ID NO:33).

Preferred antagonist peptides include those having sequences which coincide with the native C-

terminal sequence of an IL-16 starting from the residue Arg/Lys, which is Arg¹⁰⁶ for human IL-16, or the corresponding positions of other mammalian IL-16 molecules. Examples of such peptides include 6-mers
5 RRKSLQ (SEQ ID NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID NO:19), KRKSMQ (SEQ ID NO:20), 8-mers RRKSLQSK (SEQ ID NO:24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ ID NO:26), RRKSCMSK (SEQ ID NO:27), and KRKSMQSK (SEQ ID NO:28). Preferred peptides include RRKSLQ (SEQ ID
10 NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID NO:19), RRKSLQSK (SEQ ID NO:24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ ID NO:26), and RRKSCMSK (SEQ ID NO:27). Homologs and analogs of any of these tetramers are also contemplated by the present invention.

15 The IL-16 antagonist peptides of the present invention can be made by a variety of well known techniques. For example, the peptides can be chemically synthesized using standard solid-phase synthetic techniques, initially described by Merrifield
20 in *J. Am. Chem. Soc.* 85:2149-2154 (1963), or the solution methods as described in *The Proteins*, Vol. II. 3d Ed., Neurath, H. et al., Eds., p. 105-237, Academic Press, New York, N.Y. (1976). See also Bodanszky, et al. *Peptide Synthesis*, John Wiley & Sons, 2d Ed.,
25 (1976); and J. Stuart and J.D. Young, *Solid Phase Peptide Synthesis*, Pierce Chemical Company, Rockford, Ill., (1984). Appropriate protective groups for use in different peptide syntheses are described in the above-mentioned texts as well as in J.F.W. McOmie, *Protective
30 Groups in Organic Chemistry*, Plenum Press, New York, N.Y. (1973).

Additionally, the peptides of the present invention can also be prepared by recombinant DNA techniques. Nucleotide sequences coding for peptides of the present invention can be readily made by those skilled in the art and then inserted into an expression vector for producing the subject peptide in an appropriate host cell. Recombinantly produced peptides can be purified following routine procedures.

Nucleic acid molecules coding for an IL-16 antagonist peptide of the present invention, and expression vectors which include any of such nucleic acid molecules, as well as related host cells containing such nucleotide sequences or vectors, are also contemplated by the present invention.

In a further aspect, the invention provides antibodies raised against the IL-16 antagonist peptides of the present invention. The antibodies of the present invention do not include mAb14.1 or mAb 17.1 (see, Cruikshank et al., *Proc. Natl. Acad. Sci. USA* 91(11):5109-5113, 1994 Hessel et al., *J. Immunol.* 160: 2998-3005, 1998 and Keane et al., *J. Immunol.* 160: 5945-5954, 1998).

Preferably, the antibodies of the present invention are raised against those IL-16 antagonist peptides whose sequences coincide with the corresponding sequences of a mammalian IL-16 protein, preferably, human IL-16. According to the present invention, such antibodies can also inhibit the IL-16 function by binding to the peptide epitopes of an IL-16 molecule required for interacting with an IL-16 receptor, thereby blocking and neutralizing at least one IL-16-mediated biological activity. The antibodies

of the present invention do not include mAb14.1 or mAb 17.1 (see, Hessel et al., *J. Immunol.* 160: 2998-3005, 1998, and Keane et al., *J. Immunol.* 160: 5945-5954, 1998).

5 The antibodies of the present invention can be generated by well-known methods. The peptides, in combination with Freund's adjuvant, can be injected into an appropriate animal such as rabbit, mice, cow, guinea pig, rat, donkey and the like. The peptides can
10 be coupled to a carrier polypeptide, e.g., KLH, prior to immunization as described in Ausubel et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York.

15 Both polyclonal antibodies and monoclonal antibodies can be prepared using the immunized animal. The procedure for making polyclonal and monoclonal antibodies is well known in the art and can be found in, e.g., Harlow, E. and Lane, D., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, 1988.

20 Polyclonal antibodies can be readily purified from the serum of the immunized animal using a number of well known protein purification procedures such as affinity chromatography. Monoclonal clonal antibodies can be prepared by following the standard hybridoma techniques
25 (see e.g. Kohler et al., *Nature* 256:495, 1975).

Briefly, the spleens of the immunized animal can be removed, and their lymphocytes fused to an immortal cell line. The resulting hybridomas can be screened initially by binding affinity to the relevant peptide
30 antigen, which can be determined by various immuno assays such as ELISA. Hybridomas that produce monoclonal antibodies specific for the relevant peptide

antigen can be further screened for the ability of inhibiting at least one IL-16 mediated biological activity, such as chemotaxis of CD4+ T cells. Such IL-16-inhibiting antibodies are considered to be useful antagonists in the invention.

Functional derivatives of the monoclonal antibodies of the present invention are also contemplated. "Functional derivatives" refer to antibody molecules or fragments thereof that are derived from the instant monoclonal antibodies and that have retained the antigen specificity of the instant monoclonal antibodies. Examples of functional derivatives include Fab, Fab', F(ab')₂ of the present mAbs, single chain antibodies, humanized antibodies and the like.

A single-chain antibody (SAb) is created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule. Such single-chain antibody variable fragments (Fvs) can be fused to all or a portion of the constant domains of the heavy chain of an immunoglobulin molecule, if necessary. The use of sAb avoids the technical difficulties in the introduction of more than one gene construct into host cells. Single chain antibodies and methods for their production are known in the art. See, e.g., Bedzyk et al. (1990) *J. Biol. Chem.*, 265:18615; Chaudhary et al. (1990) *Proc. Natl. Acad. Sci.*, 87:9491; U.S. Patent No. 4,946,778 to Ladner et al.; and U.S. Patent No. 5,359,046 to Capon et al.

The monoclonal antibodies of the present invention can be humanized to reduce the immunogenicity for use in humans. For example, to humanize a monoclonal antibody raised in mice, one approach is to make mouse-human chimeric antibodies having the original variable region of the murine mAb, joined to constant regions of a human immunoglobulin. Chimeric antibodies and methods for their production are known in the art. See, e.g., Cabilly et al., European Patent Application 125023 (published Nov. 14, 1984); Taniguchi et al., European patent Application 171496 (published Feb. 19, 1985); Morrison et al., European Patent Application 173494 (published Mar. 5, 1986); Neuberger et al., PCT Application WO 86/01533, (published Mar. 13, 1986); Kudo et al., European Patent Application 184187 (published Jun. 11, 1986); Robinson et al., International Patent Publication #PCT/US86/02269 (published 7 May 1987); Liu et al., *Proc. Natl. Acad. Sci. USA* 84:3439-3443 (1987); Sun et al., *Proc. Natl. Acad. Sci. USA* 84:214-218 (1987); Better et al., *Science* 240:1041-1043 (1988). These references are incorporated herein by reference. Generally, DNA segments encoding the H and L chain antigen-binding regions of the murine mAb can be cloned from the mAb-producing hybridoma cells, which can then be joined to DNA segments encoding C_H and C_L regions of a human immunoglobulin, respectively, to produce murine-human chimeric immunoglobulin-encoding genes. Humanized antibodies can be made using a second approach, i.e., to construct a reshaped human antibody, which has been described in, e.g., Maeda et al., *Hum. Antibod.*

Hybridomas 2: 124-134, 1991, and Padlan, *Mol. Immunol.* 28: 489-498, 1991.

A related aspect of the present invention is directed to methods of generating antibodies specific for the IL-16 antagonist peptides of the present invention by using such peptides as immunogens.

In another embodiment of the present invention, one or more IL-16 antagonists, e.g., IL-16 antagonist peptides or antibodies, are included in pharmaceutical compositions. Such pharmaceutical compositions are used in the treatment of IL-16 mediated disorders, such as IL-16 mediated inflammatory diseases.

The pharmaceutical compositions of the present invention can also include other appropriate active ingredients, such as known anti-inflammatory agents, e.g., anti-CD4 antibodies, anti-TNF α antibodies, NSAIDS, steroids, cyclosporin-A or cytotoxic drugs.

According to the present invention, the pharmaceutical compositions also includes a pharmaceutically acceptable carrier.

As used herein, a pharmaceutically acceptable carrier includes any and all solvents, dispersion media, isotonic agents and the like. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the active ingredients contained therein, its use in practicing the methods of the present invention is appropriate. The carrier can be liquid, semi-solid, e.g. pastes, or solid carriers. Examples of carriers include oils, water, saline

solutions, alcohol, sugar, gel, lipids, liposomes, resins, porous matrices, binders, fillers, coatings, preservatives and the like, or combinations thereof.

5 In accordance with the present invention, the active ingredients of the present pharmaceutical compositions can be combined with the carrier in any convenient and practical manner, e.g., by admixture, solution, suspension, emulsification, encapsulation, absorption and the like, and can be made in
10 formulations such as tablets, capsules, powder, syrup, suspensions that are suitable for injections, implantations, inhalations, ingestions or the like. When appropriate, the pharmaceutical compositions of the present invention should be made sterile by well
15 known procedures. For example, solutions can be made sterile by filter sterilization or autoclave. To obtain a sterile powder, sterilized solutions can be vacuum-dried or freeze-dried as necessary.

20 Another embodiment of the present invention provides methods of interfering with, blocking or otherwise preventing the interaction or binding of IL-16 with an IL-16 receptor by employing the IL-16 antagonists contemplated by the present invention.

25 In a further aspect of the present invention, the pharmaceutical compositions of the present invention are employed for the treatment of IL-16 mediated pathological disorders. Thus, the present invention provides methods of treating an IL-16-mediated disorder in a subject by administering a
30 therapeutically effective amount of a pharmaceutical composition of the present invention.

By "an IL-16-mediated disorder" is meant a pathological disorder, the onset, progression or the persistence of the symptoms of which requires the participation of IL-16 molecules. Particularly, IL-16-mediated disorders contemplated by the present invention include asthma, rheumatoid arthritis, inflammatory bowel disease, Graves' disease, multiple sclerosis, lupus and bullous pemphigoid.

The term "treatment" refers to effective inhibition of the IL-16 activity so as to prevent or delay the onset, retard the progression or ameliorate the symptoms of the disorder.

The term "subject" refers to any mammalian subject. Preferably, the subject is a human subject.

According to the present invention, for treating an IL-16-mediated disorder in a mammalian subject, preferred pharmaceutical compositions for use are those constituted with IL-16 antagonist peptides or antibodies that effectively antagonize the function of the IL-16 molecule of such mammalian species.

The term "therapeutically effective amount" means the dose required to effect an inhibition of the IL-16 activity so as to prevent or delay the onset, slow down the progression or ameliorate the symptoms of the disorder.

Precise dosages depend on depends on the disease state or condition being treated and other clinical factors, such as weight and condition of the subject, the subject's response to the therapy, the type of formulations and the route of administration. The precise dosage to be therapeutically effective and non-detrimental can be determined by those skilled in

the art. As a general rule, a suitable dose of a pharmaceutical composition for the administration to adult humans ranges from about 0.001 mg to about 20 mg per kilogram of body weight, more preferably, in the
5 range of about 0.01 mg to about 5mg per kilogram of body weight. The peptides should preferably be administered in an amount of at least about 50 mg per dose, more preferably in an amount up to about 500 mg per dose. Since the peptide compositions of this
10 invention will eventually be cleared from the bloodstream, re-administration of the compositions may be required. Alternatively, implantation or injection of the peptides provided in a controlled release matrix can be employed.

15 The pharmaceutical compositions of the present invention can be administered to the subject in any practical and convenient manner. The routes of administration which can be employed include the oral, ophthalmic nasal, topical, transdermal, or parenteral
20 (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular). In addition, the pharmaceutical compositions can be introduced into the body, by injection or by surgical implantation or attachment, proximate to a preselected tissue or organ
25 site such that a significant amount of an active substance is able to enter the site by direct diffusion, and preferably, in a controlled release fashion.

30 This invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. The terms and expressions which have been employed in

the present disclosure are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof. It is to be understood that various modifications are possible within the scope of the invention. All the publications mentioned in the present disclosure are incorporated herein by reference.

10

EXAMPLE 1

Materials and Methods

Peptides

Synthetic oligopeptides corresponding to native or altered C-terminal IL-16 sequences were made at the commercial facilities of Research Genetics, Inc. (Atlanta, GA).

Cell preparation

Human peripheral blood mononuclear cells (PBMC) were isolated as described (Center, et al., *J. Immunol.* 128:256, 1982; Cruikshank, et al., *J. Immunol.* 128:2569, 1982 and Cruikshank, et al., *J. Immunol.* 138:3817, 1987) from the blood of healthy volunteers by density centrifugation on Ficoll-Paque (Pharmacia, Piscataway, NJ). The mononuclear cell layer was washed with medium 199 (M.A. Bioproducts, Walkersville, MD) supplemented with 0.4% bovine serum albumin, 25 mM HEPES buffer, and 100 U/ml of penicillin and 100 µg/ml streptomycin (M199-HPS). Samples were enriched for T lymphocytes by nylon wool adherence as described (Julius, et al., *Eur. J. Immunol.* 3:645, 1973). The nonadherent cells were >95% CD3⁺ as determined by flow cytometry.

Recombinant Proteins

Recombinant human IL-16 corresponding to the 121 C-terminal amino biologically active cytokine cleaved from natural pro-IL-16 was produced in *E. coli* as a polyhistidine fusion protein using the expression

vector pET-30 LIC (Novagen, Madison, WI). Following
lysis of transformed bacteria, the protein was purified
by metal chelation chromatography and the N-terminal
polyhistidine tag was removed by cleavage with
5 enterokinase.

The native IL-16 expression vector (pET-
30/IL-16¹²¹) was used as a template for PCR mutagenesis
to create four recombinant IL-16 (rIL-16) mutant
constructs with progressive four amino acid deletions
10 at the C-terminus (C-4 to C-16), as well as deletions
of 12 or 22 N-terminal residues. Two double deletion
constructs lacking the first 12 or 22 N-terminal
residues as well as the last 16 C-terminal residues of
IL-16 were also produced. Point mutations in C-
15 terminal residues of rIL-16 were generated by site-
directed mutagenesis using the Stratagene Quick Change
Kit (Stratagene, La Jolla, CA) according to the
manufacturer's specifications. The point mutations
included alanine substitution for Arg¹⁰⁶, Arg¹⁰⁷, and
20 Arg¹⁰⁶ plus Arg¹⁰⁷.

Western blot analysis

Native and mutated rIL-16 proteins were
subjected to electrophoresis through a 15% SDS-
25 polyacrylamide gel, then electrophoretically
transferred to nitrocellulose membranes. The membranes
were probed with either polyclonal rabbit anti-rIL-16
or a murine anti-rIL-16 mAb designated clone 17.1.
Secondary horse radish peroxidase (HRP)-conjugated
30 anti-immunoglobulins were used at a concentration of
1:5000, and the signal was visualized by
chemiluminescence (Pierce, Rockford, IL).

Chemotaxis assay

Cell migration was measured using a modified Boyden chemotaxis chamber as described (Center, et al., *J. Immunol.* 128:256, 1982; Cruikshank, et al., *J. Immunol.* 128:2569, 1982, and Cruikshank, et al., *J. Immunol.* 138:3817, 1987). Cells were suspended (5×10^6 cells/ml) in M199-HPS and loaded into the upper wells, separated by an 8 μ m pore size nitrocellulose membrane from lower wells. The lower wells were loaded with control buffer or experimental chemoattractant stimuli, with or without synthetic peptides. After a 4 h incubation at 37°C, the membranes were removed and stained with hematoxylin, dehydrated by sequential washes in ethanol and propanol, then washed in xylene to clarify the filter for cell counting by light microscopy. Cell migration was quantified by counting the number of cells in the filter that had moved beyond a depth of 50 μ m in five separate fields in duplicate wells for all conditions. Cell counts were compared with unstimulated control cell migration which was normalized to 100%. Results are expressed as mean % control migration and the data analyzed for statistical significance ($P < 0.05$) by Student's *t* test.

Mixed lymphocyte reaction

Stimulator cells for mixed lymphocyte reactions were prepared by incubating PBMC (10^6 /ml) with 25 μ g/ml mitomycin C for 30 min. The cells were then washed four times with RPMI 1640 medium supplemented with 25 mM HEPES buffer, 100 U/ml

penicillin, and 100 µg/ml streptomycin (RPMI 1640-HPS), then resuspended in RPMI 1640-HPS supplemented with 10% fetal bovine serum (complete medium) at 10^6 cells/ml. Responder cells were prepared from an unrelated donor, 5 suspended in complete medium at 10^6 cells/ml, and pre-incubated (1 h, 37 °C) with control buffer, or with rIL-16 or mutated rIL-16 constructs (10^{-9} M to 10^{-11} M). Stimulator cells were then added (1:1) and the cell 10 mixtures were transferred in quadruplicate to 96-well round-bottom plates. Cell cultures were pulsed with [3 H] thymidine on day 5, harvested with a Titertek cell harvester, and counted in a Becton Dickinson scintillation counter on day 6. Results are expressed as mean % cpm above background $\pm$ SEM. Data were 15 analyzed for statistical significance ($P < 0.05$) by Student's t test.

EXAMPLE 2
Inhibition of IL-16-Stimulated T Lymphocyte
Motility by C-terminal Oligopeptides

A series of oligopeptides derived from the 16 C-terminal of human IL-16 residues were prepared (**Figure 1**) and tested for their ability to stimulate the T lymphocyte motility using a modified Boyden chemotaxis chamber assay.

Human T lymphocytes were loaded in the upper wells, and rIL-16 at concentrations of 10^{-9} M, 10^{-10} M or 10^{-11} M was loaded in the lower wells, in the presence or absence of two 8-mer peptides corresponding to amino acids Arg¹⁰⁶ to Lys¹¹³ (SEQ ID NO:24), and Glu¹¹⁴ to Ser¹²¹ (SEQ ID NO:46) of IL-16. As shown in **Figure 2,A**, only the Arg¹⁰⁶ to Lys¹¹³ peptide (SEQ ID NO:24) inhibited IL-16 in this assay. The six-mer RRKSLQ (SEQ ID NO:17) also inhibited IL-16-stimulated T cell migration, but a scrambled peptide containing the same residues in a randomly chosen sequence (SEQ ID NO:47) demonstrated no inhibitory activity. To further define the residues mediating inhibition, the eight residue sequence from Arg¹⁰⁶ to Lys¹¹³ was divided into RRKS (SEQ ID NO:2) and LQSK (SEQ ID NO:48). Only RRKS (SEQ ID NO:2) inhibited IL-16 chemoattractant activity (**Figure 2,A**).

The contribution of individual residues within RRKS was analyzed by alanine scanning (**Figure 2,B**). Substitution of either Arg¹⁰⁶ or Arg¹⁰⁷ was associated with loss of inhibitory activity against IL-16-induced chemotaxis. In contrast, the peptides RRAS (SEQ ID NO:5) and RRKA (SEQ ID NO:6) inhibited IL-16 as effectively as the native RRKS (SEQ ID NO:2).

To test whether inhibition by RRKS (SEQ ID NO:2) of chemotaxis in response to CD4 stimulation is specific for IL-16, peptide RRKS (SEQ ID NO:2) was tested in combination with two different CD4 ligands that induce T cell motility, HIV-1 gp120 (strain HIV-1_{3B}) and Leu 3a mAb. Cell migration in response to HIV-1 gp120 (13), or divalent anti-CD4 mAb Leu 3a was not blocked by this peptide (**Figure 3**).

These data demonstrate that the four-residue peptide RRKS can effectively and specifically inhibit the chemoattractant activity of IL-16.

EXAMPLE 3
Chemoattractant Activity
of IL-16 Deletion Mutants

5

10

15

20

25

IL-16 mutant constructs were created with progressive deletions of 4 C-terminal amino acids from C-4 through C-16 (**Figure 4**). The C-12 construct terminates at Ser¹⁰⁸, retaining the RRKS motif. The C-16 construct terminates at Ile¹⁰⁵, deleting RRKS and succeeding downstream residues. These mutant IL-16 molecules were tested in chemotaxis assays. As shown in **Figure 5, A**, C-12 was active as native rIL-16, while the C-16 deletion completely eliminated the chemoattractant activity. In similar experiments, C-4 and C-8 deletion constructs demonstrated chemoattractant activities comparable to native rIL-16. These results, consistent with the peptide studies, indicate that residues within the RRKS motif are required for IL-16-stimulated chemoattractant activity.

To determine whether the N-terminal structures of IL-16 contribute to chemotactic signaling, two additional constructs with deletion of 12 or 22 N-terminal amino acids were tested. Both the N-12 and N-22 deletion mutants demonstrated chemoattractant activity comparable to native IL-16 (**Figure 5, A**). These results indicate that the N-terminal domain is not required in receptor interactions activating cell motility.

EXAMPLE 4
Contribution of Specific C-terminal Residues
to IL-16 Chemoattractant Activity

5 To determine the contribution of individual
residues within the RRKS motif to chemoattractant
signaling, and to test the activity of IL-16 mutants
with minimal structural alterations, a series of point
10 mutations using alanine substitution were generated
(**Figure 4**). Replacement of Arg¹⁰⁷ alone, or Arg¹⁰⁶ plus
Arg¹⁰⁷, completely abrogated chemoattractant activity of
the recombinant protein (**Figure 5,B**). In contrast,
substitution of Arg¹⁰⁶ alone retained full activity.
15 The identical pattern of motile responses was observed
using a different IL-16-responsive cell type, human
peripheral blood monocytes.

 To test whether multimer formation is
disrupted by deletion or point mutation, the above-
20 generated mutant IL-16 molecules were assessed by HPLC.
All of these constructs formed multimers similar to
native IL-16. These observations indicate that
mutation of Arg¹⁰⁷ directly interferes with CD4 binding
or activation by IL-16.

EXAMPLE 5
Western Analysis of IL-16 Mutant Proteins

5 Rabbit polyclonal anti-IL-16 Ab, as well as a
murine monoclonal anti-IL-16 (clone 17.1) were
generated using rIL-16 as an immunogen. This mAb was
isolated by screening hybridoma supernatants for
neutralization of IL-16 chemoattractant activity.
10 Western blot analysis was performed with native rIL-16
and the C-terminal deletion mutants (**Figure 6**), using
either the polyclonal Ab or the mAb for detection. As
expected, the polyclonal Ab recognized native rIL-16
and all of the deletion mutants. The mAb 17.1 detected
15 native rIL-16 and the deletion mutants lacking 4, 8, or
12 C-terminal residues, as well as the N-terminal
deletion mutants. However, mAb 17.1 failed to bind to
C-16. The epitope for the neutralizing anti-IL-16 mAb
17.1 therefore maps to the identical domain shown to be
20 required for IL-16 chemoattractant activity by peptide
inhibition and mutation experiments.

EXAMPLE 6
Inhibition of the Mixed Lymphocyte Reaction

5 To determine whether other biological
activities of IL-16 are mediated by the C-terminal
domain, the native and mutated rIL-16 constructs were
tested for their capacity of inhibiting the one way
MLR. Responder T lymphocytes were pre-treated with
10 rIL-16 or control buffer, then cultured with mitomycin
C-treated stimulator PBMC from an unrelated donor.
Pre-treatment with 10^{-8} M native rIL-16 reduced
thymidine incorporation on day 6 by nearly 70%,
compared with untreated cells. Surprisingly, IL-16
15 mutants with the C-terminal point mutations which lost
chemoattractant activity retained full capacity to
inhibit the MLR (**Figure 7**). The C-16 deletion mutant
was nearly as active as native rIL-16, with a ~1 log
shift of the dose response (**Figure 8**). Deletion of 12
20 or 22 N-terminal residues resulted in a similar pattern
as C-16; MLR inhibition was reduced but not eliminated.
In contrast, constructs that combined the C-16 deletion
with N-12 or N-22 lost all capacity to inhibit the MLR.

25 These data demonstrate that both N-terminal
and C-terminal domains of IL-16 are involved in
receptor binding and activation, and that the
structural elements of IL-16 required for stimulating T
cell motility are different from those required for
inhibition of Mixed Lymphocyte Reaction.

30

Table I

	<u>Seq ID</u>	<u>Sequence</u>	<u>Source</u>
	1	$X_{aa0}RX_{aa1}X_{aa2}$	
5	2	RRKS	h, ag, rm, mac, man,
		z	
	3	RRTS	m
	4	KRKS	sm, at
	5	RRAS	analog
10	6	RRKA	analog
	7	RRTA	analog
	8	$X_{aa1}X_{aa2}X_{aa0}R$	
15	9	VIRR	h, m, ag, rm, mac,
		man	
	10	VLRR	z
	11	VIKR	sm, at
	12	$X_{aa1}X_{aa0}RX_{aa2}$	
20	13	IRRK	h, ag, rm, mac, man
	14	IRRT	m
	15	LRRK	z
	16	IKRK	sm, at
25	17	RRKSLQ	h, ag, rm, mac, man
	18	RRTSLQ	m
	19	RRKSCM	z
	20	KRKSMQ	sm, at
	21	RRASLQ	analog
30	22	RRKALQ	analog
	23	RRTALQ	analog

	24	RRKSLQSK	h
	25	RRTSLQCK	m
	26	RRKSLQPK	ag, rm, man
	27	RRKSCMSK	z
5	28	KRKSMQSK	sm, at
	29	RRASLQSK	analog
	30	RRKALQSK	analog
	31	RRTALQCK	analog
	32	RRASLQCK	analog
10			
	33	RRKSLQSKETTAAGDS	h
	34	RRTSLQCKQTTASADS	m
	35	RRASLQSKETTAAGDS	analog
	36	RRKALQSKETTAAGDS	analog
15	37	RRTALQCKQTTASADS	analog
	38	RRASLQCKQTTASADS	analog
	39	Human IL-16	
	40	Murine IL-16	
20	41	African green monkey IL-16 = rhesus monkey = mangeby	
	42	macaque IL-16	
	43	zebu IL-16	
	44	squirrel monkey IL-16	
25	45	Aotus trivirgatus IL-16	
	46	ETTAAGDS	
	47	RSQRLK	
	48	LQSK	

30 Abbreviations:

h = human, m = murine, ag = African green monkey,
rh = rhesus monkey, man = mangeby, z = zebu,

mac = macaque, sm = squirrel monkey,
at = Aotus trivirgatus

WE CLAIM:

1. An IL-16 antagonist peptide.

2. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKS (SEQ ID NO:2), RRTS (SEQ ID NO:3), KRKS (SEQ ID NO:4), RRAS (SEQ ID NO:5), RRKA (SEQ ID NO:6) and RRTA (SEQ ID NO:7).

3. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKSLQ (SEQ ID NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID NO:19), KRKSMQ (SEQ ID NO:20), RRASLQ (SEQ ID NO:21), RRKALQ (SEQ ID NO:22) and RRTALQ (SEQ ID NO:23).

4. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRKSLQSK (SEQ ID NO: 24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ ID NO:26), RRKSCMSK (SEQ ID NO:27), KRKSMQSK (SEQ ID NO:28), RRASLQSK (SEQ ID NO:29), RRKALQSK (SEQ ID NO:30), RRTALQCK (SEQ ID NO:31) and RRASLQCK (SEQ ID NO:32).

5. An IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRTSLQCKQTTASADS (SEQ ID NO:34), RRASLQSKETTAAGDS (SEQ ID NO:35), RRKALQSKETTAAGDS (SEQ ID NO:36), RRTALQCKQTTASADS (SEQ ID NO:37) and RRASLQCKQTTASADS (SEQ ID NO:38).

6. An IL-16 antagonist peptide comprising $X_{aa0}RX_{aa1}X_{aa2}$ (SEQ ID NO:1), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} are any amino acids.

7. The IL-16 antagonist peptide of Claim 6, wherein X_{aa1} is selected from Lys, Thr, or Ala; and X_{aa2} is selected from Serine or Ala.

5 8. The IL-16 antagonist peptide of Claim 6, wherein X_{aa0} is Arg.

9. The IL-16 antagonist peptide of Claim 8, wherein X_{aa1} is selected from Lys, Thr, or Ala; and
10 X_{aa2} is Ser or Ala.

10. The IL-16 antagonist peptide of Claim 6, wherein X_{aa0} is Lys.

15 11. The IL-16 antagonist peptide of Claim 10, wherein X_{aa1} is selected from Lys, Thr, or Ala; and X_{aa2} is Ser or Ala.

12. The IL-16 antagonist peptide of Claim 8 or
20 10, wherein the tetrameric sequence coincides with the native sequence of a mammalian IL-16.

13. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRKS
25 (SEQ ID NO:2), RRTS (SEQ ID NO:3), KRKS (SEQ ID NO:4), RRAS (SEQ ID NO:5), RRKA (SEQ ID NO:6) and RRTA (SEQ ID NO:7).

14. An IL-16 antagonist peptide comprising
30 $X_{aa1}X_{aa2}X_{aa0}R$ (SEQ ID NO:8), wherein X_{aa0} is Arg or Lys, and X_{aa1} and X_{aa2} are any amino acids.

15. The IL-16 antagonist peptide of Claim 14,
wherein X_{aa1} is Val and X_{aa2} is Ile or Leu.

16. The IL-16 antagonist peptide of Claim 14,
5 wherein X_{aa0} is Arg.

17. The IL-16 antagonist peptide of Claim 16,
wherein X_{aa1} is Val and X_{aa2} is Ile or Leu.

10 18. The IL-16 antagonist peptide of Claim 14,
wherein X_{aa0} is Lys.

19. The IL-16 antagonist peptide of Claim 18,
wherein X_{aa1} is Val and X_{aa2} is Leu or Ile.

15 20. The IL-16 antagonist peptide of Claim 16 or
18, wherein the tetrameric sequence coincides with the
native sequence of a mammalian IL-16.

20 21. An IL-16 antagonist peptide comprising a
sequence selected from the group consisting of VIRR
(SEQ ID NO:9), VLRR (SEQ ID NO:10) and VIKR (SEQ ID
NO:11).

25 22. An IL-16 antagonist peptide comprising
 $X_{aa1}X_{aa0}RX_{aa2}$ (SEQ ID NO:12), wherein X_{aa0} is Arg or Lys,
and X_{aa1} and X_{aa2} are any amino acids.

30 23. The IL-16 antagonist peptide of Claim 22,
wherein X_{aa1} is Ile or Leu and X_{aa2} is Lys, Thr or Ala.

24. The IL-16 antagonist peptide of Claim 22,
wherein X_{aa0} is Arg.

25. The IL-16 antagonist peptide of Claim 24,
wherein X_{aa1} is selected from Ile or Leu and X_{aa2} is Lys,
Thr or Ala.

26. The IL-16 antagonist peptide of Claim 22,
wherein X_{aa0} is Lys.

27. The IL-16 antagonist peptide of Claim 26,
wherein X_{aa1} is selected from Leu or Ileu; and X_{aa2} is
Lys, Thr or Ala.

28. The IL-16 antagonist peptide of Claim 24 or
26, wherein the tetrameric sequence coincides with the
native sequence of a mammalian IL-16.

29. An IL-16 antagonist peptide comprising a
sequence selected from the group consisting of IRRK
(SEQ ID NO:13), IRRT (SEQ ID NO:14), LRRK (SEQ ID
NO:15) and IKRK (SEQ ID NO:16).

30. An IL-16 antagonist peptide comprising a
sequence selected from the group consisting of RRKSLQ
(SEQ ID NO:17), RRTSLQ (SEQ ID NO:18), RRKSCM (SEQ ID
NO:19), KRKSMQ (SEQ ID NO:20), RRASLQ (SEQ ID NO:21),
RRKALQ (SEQ ID NO:22) and RRTALQ (SEQ ID NO:23).

31. An IL-16 antagonist peptide comprising a
sequence selected from the group consisting of RRKSLQSK
(SEQ ID NO:24), RRTSLQCK (SEQ ID NO:25), RRKSLQPK (SEQ

ID NO:26), RRKSCMSK (SEQ ID NO:27), KRKSMQSK (SEQ ID NO:28), RRASLQSK (SEQ ID NO:29), RRKALQSK (SEQ ID NO:30), RRTALQCK (SEQ ID NO:31) and RRASLQCK (SEQ ID NO:32).

5

32. An IL-16 antagonist peptide comprising a sequence selected from the group consisting of RRTSLQCKQTTASADS (SEQ ID NO:34), RRASLQSKETTAAGDS (SEQ ID NO:35), RRKALQSKETTAAGDS (SEQ ID NO:36),
10 RRTALQCKQTTASADS (SEQ ID NO:37) and RRASLQCKQTTASADS (SEQ ID NO:38).

33. An isolated nucleic acid molecule coding for any one of the peptide of Claims 1-4, 6, 14 or 22.

15

34. An antibody raised against the peptide of any one of Claims 1-4, 6, 14 or 22.

35. A pharmaceutical composition comprising the peptide of any of Claims 1-4, 6, 14 or 22 and a
20 pharmaceutically acceptable carrier.

36. A pharmaceutical composition comprising the antibody of Claim 34.

25

37. A method of treating an IL-16 mediated disorder in a subject, comprising administering to the subject a therapeutically effective amount of the peptide of any of Claims 1-4, 6, 14 or 22 and a
30 pharmaceutically acceptable carrier.

38. The method of Claim 37, wherein said IL-16 mediated disorder is an inflammatory disease selected from asthma, rheumatoid arthritis, inflammatory bowel disease, Graves' disease, multiple sclerosis, lupus or
5 bullous pemphigoid.

39. The method of Claim 38, further comprising simultaneously administering an anti-inflammatory agent selected from an anti-CD4 antibody, an anti-TNF α
10 antibody, NSAIDS, steroids, cyclosporin-A or a cytotoxic drug.

40. An IL-16 antagonist.

15 41. A pharmaceutical composition comprising an IL-16 antagonist and a pharmaceutically acceptable carrier.

20 42. A method of treating an IL-16 mediated disorder comprising blocking the interaction of IL-16 with an IL-16 receptor by the administration of an IL-16 antagonist.




FIGURE 1




FIGURE 2

3/9




FIGURE 3




FIGURE 4

5/9




FIGURE 5




FIGURE 6

7/9




FIGURE 7

8/9




FIGURE 8

Human (SEQ ID NO:39)
 saasasaasd vsvestaeat vctvtlekms aglgsflegg kgslhgdkpl tinrifkgaa seqsetvqpg deilqlggta
 mqgltrfeaw niikalpdgp vtivir~~rk~~sl qskettaagd s

Murine (SEQ ID NO:40)
 saasasaasd isveskeatv ctvtlektsa glgsfleggk gslhgdkplt inrifkgdrt gemvqpgdei lqlagtavqg
 ltrfeawni kalpdgpvti vir~~rt~~slqck qttasads

African green monkey = Rhesus monkey = Mangeby (SEQ ID NO:41)
 saasasaasd vsvestaeat vytvtlekms aglgsflegg kgslhgdkpl tinrifkgaa seqsetiqpg deilqlagta
 mqgltrfeaw niikalpdgp vtivir~~rk~~sl qpkettaaad s

Macaque (SEQ ID NO:42)
 saasasaasd vsvestaeat vytvtlekms aglgsflegg kgslhgdkpl tinrifkgaa seqsetiqpg deilqlagta
 mqgltrfeaw niikalpdgp vttvir~~rk~~sl qpkettaaad s

Zebu (SEQ ID NO:43)
 ssgsasvdse shrireatvc tvtlektsag lgsfleggk slhgdklltv nrilkgwleq sdtvqpgdei vhlagtamqd
 ltrfeawnii kalpdgpvti vl~~rr~~kscmsk gtpaagd

Squirrel monkey (SEQ ID NO:44)
 saasasaasd vsvdstaeat vctvtlekms gglgsflegg kslqgdkpl tinrifkgaa seqsetvqpg deilhlagta
 mqgltrfeaw niikalpdgp vtivir~~rk~~ksm qskgttsaagd

Aotus trivirgatus (SEQ ID NO:45)
 saasvsaasd vsvdstaeat vctvtlekms gglgsflegg kgslhgdkpl tinrifkgaa seqsetvqpg deilhlagta
 mqgltrfeaw niikalpdgp vtivir~~rk~~ksm qskgttsaagd s

Figure 9